CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ergomed PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ergomed PLC
1 Occam Court, Occam Road
Phone: +44 1483503205p:+44 1483503205 Guildford, GU2 7HJ  United Kingdom Fax: +44 1483307929f:+44 1483307929
On 11/14/2023, the Company was acquired by Permira Funds, which is owned by Permira Advisers LLP.
This company is no longer actively traded on any major stock exchange.
Business Summary
Ergomed PLC is a United Kingdom-based company that is primarily focused on providing specialized services to the biopharmaceutical industry. The Company operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). Its CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. Its PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The Company serves over 100 countries. It operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Company's subsidiaries include PrimeVigilance Inc., PrimeVigilance USA Inc., PrimeVigilance s.r.o., PharmInvent regulatory s.r.o., PrimeVigilance Japan K.K., Haemostatix Limited and Sound Opinion Limited.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022Yes----

Industries
SIC Code Description
7389 Business services, not elsewhere classified
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board MiroslavReljanovic 64 1/1/2019
Chief Financial Officer, Executive Director JonathanCurtain 46 2/3/2023 11/17/2022
Chief Transformation and Technology Officer Michael W.Spiteri 60 11/17/2022 10/2/2018
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Ashfield Pharmacovigilance, Inc. 100 Regency Forest Drive Cary NC United States

Business Names
Business Name
Ashfield Pharmacovigilance
Ergomed CDS GmbH
Ergomed Clinical Research FZ LLC
16 additional Business Names available in full report.

General Information
Number of Employees: 1,437 (As of 12/31/2022)
Outstanding Shares: 52,084,254 (As of 11/10/2023)
Stock Exchange: LON
Fax Number: +44 1483307929


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024